The average one-year price target for Caribou Biosciences (NasdaqGS:CRBU) has been revised to $12.37 / share. This is an increase of 38.57% from the prior estimate of $8.92 dated April 25, 2026.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $4.04 to a high of $33.60 / share. The average price target represents an increase of 483.37% from the latest reported closing price of $2.12 / share.
What is the Fund Sentiment?
There are 135 funds or institutions reporting positions in Caribou Biosciences. This is an decrease of 42 owner(s) or 23.73% in the last quarter. Average portfolio weight of all funds dedicated to CRBU is 0.05%, an increase of 53.96%. Total shares owned by institutions decreased in the last three months by 3.49% to 41,853K shares. 
The put/call ratio of CRBU is 0.33, indicating a bullish outlook.
What are Other Shareholders Doing?
Pfizer holds 4,690K shares representing 4.77% ownership of the company. No change in the last quarter.
Vanguard Capital Management holds 3,767K shares representing 3.83% ownership of the company.
Kynam Capital Management holds 2,503K shares representing 2.55% ownership of the company. In its prior filing, the firm reported owning 3,068K shares , representing a decrease of 22.55%. The firm decreased its portfolio allocation in CRBU by 52.22% over the last quarter.
Renaissance Technologies holds 1,640K shares representing 1.67% ownership of the company. In its prior filing, the firm reported owning 780K shares , representing an increase of 52.41%.
Standard Life Aberdeen holds 1,213K shares representing 1.23% ownership of the company. In its prior filing, the firm reported owning 1,389K shares , representing a decrease of 14.54%. The firm increased its portfolio allocation in CRBU by 5.91% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
